Showing results (131-140 of 181) with videos related to

Sort By:
Pageof 19
Nature Biotechnology|January 24, 2007
Therapeutic targeting of a stem cell nicheGregor B Adams, Roderick P Martin, Ian R Alley, et al.
Nature Communications|October 14, 2018
EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcriptionEdward Ayoub, Michael P Wilson, Kathleen E McGrath, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 16, 2021
Reduction of leukemic burden via bone-targeted nanoparticle delivery of an inhibitor of C-chemokine (C-C motif) ligand 3 (CCL3) signalingMarian A Ackun-Farmmer, Celia A Soto, Maggie L Lesch, et al.
Calcified Tissue International|February 1, 2014
1,25(OH)₂D₃ induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming ratsAdeline H Ng, Kevin K Frick, Nancy S Krieger, et al.
The Journal of Experimental Medicine|June 2, 2005
Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool sizeSebastian Stier, Yon Ko, Randolf Forkert, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 23, 2018
Patients with advanced chronic kidney disease and vascular calcification have a large hydrodynamic radius of secondary calciprotein particlesWei Chen, Viktoriya Anokhina, Gregory Dieudonne, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2005
Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming ratsAlexander J Karnauskas, Johannes P T M van Leeuwen, Gert-Jan C M van den Bemd, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 4, 2022
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosisVandana S Mathur, David A Bushinsky, Lesley Inker, et al.
Pageof 19